Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrew Kasarskis is active.

Publication


Featured researches published by Andrew Kasarskis.


Nature Genetics | 2000

Gene ontology: tool for the unification of biology. The Gene Ontology Consortium.

Michael Ashburner; Catherine A. Ball; Judith A. Blake; David Botstein; Heather L. Butler; J. Michael Cherry; Allan Peter Davis; Kara Dolinski; Selina S. Dwight; Janan T. Eppig; Midori A. Harris; David P. Hill; Laurie Issel-Tarver; Andrew Kasarskis; Suzanna E. Lewis; John C. Matese; Joel E. Richardson; Martin Ringwald; Gerald M. Rubin; Gavin Sherlock

Genomic sequencing has made it clear that a large fraction of the genes specifying the core biological functions are shared by all eukaryotes. Knowledge of the biological role of such shared proteins in one organism can often be transferred to other organisms. The goal of the Gene Ontology Consortium is to produce a dynamic, controlled vocabulary that can be applied to all eukaryotes even as knowledge of gene and protein roles in cells is accumulating and changing. To this end, three independent ontologies accessible on the World-Wide Web (http://www.geneontology.org) are being constructed: biological process, molecular function and cellular component.


PLOS Biology | 2008

Mapping the Genetic Architecture of Gene Expression in Human Liver

Eric E. Schadt; Cliona Molony; Eugene Chudin; Ke-Ke Hao; Xia Yang; Pek Yee Lum; Andrew Kasarskis; Bin Zhang; Susanna Wang; Christine Suver; Jun Zhu; Joshua Millstein; Solveig K. Sieberts; John Lamb; Debraj GuhaThakurta; Jonathan Derry; John D. Storey; Iliana Avila-Campillo; Mark Kruger; Jason M. Johnson; Carol A. Rohl; Atila van Nas; Margarete Mehrabian; Thomas A. Drake; Aldons J. Lusis; Ryan Smith; F. Peter Guengerich; Stephen C. Strom; Erin G. Schuetz; Thomas H. Rushmore

Genetic variants that are associated with common human diseases do not lead directly to disease, but instead act on intermediate, molecular phenotypes that in turn induce changes in higher-order disease traits. Therefore, identifying the molecular phenotypes that vary in response to changes in DNA and that also associate with changes in disease traits has the potential to provide the functional information required to not only identify and validate the susceptibility genes that are directly affected by changes in DNA, but also to understand the molecular networks in which such genes operate and how changes in these networks lead to changes in disease traits. Toward that end, we profiled more than 39,000 transcripts and we genotyped 782,476 unique single nucleotide polymorphisms (SNPs) in more than 400 human liver samples to characterize the genetic architecture of gene expression in the human liver, a metabolically active tissue that is important in a number of common human diseases, including obesity, diabetes, and atherosclerosis. This genome-wide association study of gene expression resulted in the detection of more than 6,000 associations between SNP genotypes and liver gene expression traits, where many of the corresponding genes identified have already been implicated in a number of human diseases. The utility of these data for elucidating the causes of common human diseases is demonstrated by integrating them with genotypic and expression data from other human and mouse populations. This provides much-needed functional support for the candidate susceptibility genes being identified at a growing number of genetic loci that have been identified as key drivers of disease from genome-wide association studies of disease. By using an integrative genomics approach, we highlight how the gene RPS26 and not ERBB3 is supported by our data as the most likely susceptibility gene for a novel type 1 diabetes locus recently identified in a large-scale, genome-wide association study. We also identify SORT1 and CELSR2 as candidate susceptibility genes for a locus recently associated with coronary artery disease and plasma low-density lipoprotein cholesterol levels in the process.


The New England Journal of Medicine | 2011

Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany.

David A. Rasko; Dale Webster; Jason W. Sahl; Ali Bashir; Nadia Boisen; Flemming Scheutz; Ellen E. Paxinos; Robert Sebra; Chen Shan Chin; Dimitris Iliopoulos; Aaron Klammer; Paul Peluso; Lawrence Lee; Andrey Kislyuk; James Bullard; Andrew Kasarskis; Susanna Wang; John Eid; David Rank; Julia C. Redman; Susan R. Steyert; Jakob Frimodt-Møller; Carsten Struve; Andreas Petersen; Karen A. Krogfelt; James P. Nataro; Eric E. Schadt; Matthew K. Waldor

BACKGROUND A large outbreak of diarrhea and the hemolytic-uremic syndrome caused by an unusual serotype of Shiga-toxin-producing Escherichia coli (O104:H4) began in Germany in May 2011. As of July 22, a large number of cases of diarrhea caused by Shiga-toxin-producing E. coli have been reported--3167 without the hemolytic-uremic syndrome (16 deaths) and 908 with the hemolytic-uremic syndrome (34 deaths)--indicating that this strain is notably more virulent than most of the Shiga-toxin-producing E. coli strains. Preliminary genetic characterization of the outbreak strain suggested that, unlike most of these strains, it should be classified within the enteroaggregative pathotype of E. coli. METHODS We used third-generation, single-molecule, real-time DNA sequencing to determine the complete genome sequence of the German outbreak strain, as well as the genome sequences of seven diarrhea-associated enteroaggregative E. coli serotype O104:H4 strains from Africa and four enteroaggregative E. coli reference strains belonging to other serotypes. Genomewide comparisons were performed with the use of these enteroaggregative E. coli genomes, as well as those of 40 previously sequenced E. coli isolates. RESULTS The enteroaggregative E. coli O104:H4 strains are closely related and form a distinct clade among E. coli and enteroaggregative E. coli strains. However, the genome of the German outbreak strain can be distinguished from those of other O104:H4 strains because it contains a prophage encoding Shiga toxin 2 and a distinct set of additional virulence and antibiotic-resistance factors. CONCLUSIONS Our findings suggest that horizontal genetic exchange allowed for the emergence of the highly virulent Shiga-toxin-producing enteroaggregative E. coli O104:H4 strain that caused the German outbreak. More broadly, these findings highlight the way in which the plasticity of bacterial genomes facilitates the emergence of new pathogens.


Nucleic Acids Research | 2001

The Stanford Microarray Database

Gavin Sherlock; Tina Hernandez-Boussard; Andrew Kasarskis; Gail Binkley; John C. Matese; Selina S. Dwight; Shuai Weng; Heng Jin; Catherine A. Ball; Michael B. Eisen; Paul T. Spellman; Patrick O. Brown; David Botstein; J. Michael Cherry

The Stanford Microarray Database (SMD) stores raw and normalized data from microarray experiments, and provides web interfaces for researchers to retrieve, analyze and visualize their data. The two immediate goals for SMD are to serve as a storage site for microarray data from ongoing research at Stanford University, and to facilitate the public dissemination of that data once published, or released by the researcher. Of paramount importance is the connection of microarray data with the biological data that pertains to the DNA deposited on the microarray (genes, clones etc.). SMD makes use of many public resources to connect expression information to the relevant biology, including SGD [Ball,C.A., Dolinski,K., Dwight,S.S., Harris,M.A., Issel-Tarver,L., Kasarskis,A., Scafe,C.R., Sherlock,G., Binkley,G., Jin,H. et al. (2000) Nucleic Acids Res., 28, 77-80], YPD and WormPD [Costanzo,M.C., Hogan,J.D., Cusick,M.E., Davis,B.P., Fancher,A.M., Hodges,P.E., Kondu,P., Lengieza,C., Lew-Smith,J.E., Lingner,C. et al. (2000) Nucleic Acids Res., 28, 73-76], Unigene [Wheeler,D.L., Chappey,C., Lash,A.E., Leipe,D.D., Madden,T.L., Schuler,G.D., Tatusova,T.A. and Rapp,B.A. (2000) Nucleic Acids Res., 28, 10-14], dbEST [Boguski,M.S., Lowe,T.M. and Tolstoshev,C.M. (1993) Nature Genet., 4, 332-333] and SWISS-PROT [Bairoch,A. and Apweiler,R. (2000) Nucleic Acids Res., 28, 45-48] and can be accessed at http://genome-www.stanford.edu/microarray.


Human Molecular Genetics | 2010

A window into third generation sequencing

Eric E. Schadt; Steve Turner; Andrew Kasarskis

First- and second-generation sequencing technologies have led the way in revolutionizing the field of genomics and beyond, motivating an astonishing number of scientific advances, including enabling a more complete understanding of whole genome sequences and the information encoded therein, a more complete characterization of the methylome and transcriptome and a better understanding of interactions between proteins and DNA. Nevertheless, there are sequencing applications and aspects of genome biology that are presently beyond the reach of current sequencing technologies, leaving fertile ground for additional innovation in this space. In this review, we describe a new generation of single-molecule sequencing technologies (third-generation sequencing) that is emerging to fill this space, with the potential for dramatically longer read lengths, shorter time to result and lower overall cost.


The New England Journal of Medicine | 2011

The Origin of the Haitian Cholera Outbreak Strain

Chen Shan Chin; Jon Sorenson; Jason B. Harris; William P. Robins; Richelle C. Charles; Roger R. Jean-Charles; James Bullard; Dale Webster; Andrew Kasarskis; Paul Peluso; Ellen E. Paxinos; Yoshiharu Yamaichi; Stephen B. Calderwood; John J. Mekalanos; Eric E. Schadt; Matthew K. Waldor

BACKGROUND Although cholera has been present in Latin America since 1991, it had not been epidemic in Haiti for at least 100 years. Recently, however, there has been a severe outbreak of cholera in Haiti. METHODS We used third-generation single-molecule real-time DNA sequencing to determine the genome sequences of 2 clinical Vibrio cholerae isolates from the current outbreak in Haiti, 1 strain that caused cholera in Latin America in 1991, and 2 strains isolated in South Asia in 2002 and 2008. Using primary sequence data, we compared the genomes of these 5 strains and a set of previously obtained partial genomic sequences of 23 diverse strains of V. cholerae to assess the likely origin of the cholera outbreak in Haiti. RESULTS Both single-nucleotide variations and the presence and structure of hypervariable chromosomal elements indicate that there is a close relationship between the Haitian isolates and variant V. cholerae El Tor O1 strains isolated in Bangladesh in 2002 and 2008. In contrast, analysis of genomic variation of the Haitian isolates reveals a more distant relationship with circulating South American isolates. CONCLUSIONS The Haitian epidemic is probably the result of the introduction, through human activity, of a V. cholerae strain from a distant geographic source. (Funded by the National Institute of Allergy and Infectious Diseases and the Howard Hughes Medical Institute.).


Nature | 2012

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

Catherine C. Smith; Qi Wang; Chen Shan Chin; Sara Salerno; Lauren E. Damon; Mark Levis; Alexander E. Perl; Kevin Travers; Susana Wang; Jeremy P. Hunt; Patrick P. Zarrinkar; Eric E. Schadt; Andrew Kasarskis; John Kuriyan; Neil P. Shah

Effective targeted cancer therapeutic development depends upon distinguishing disease-associated ‘driver’ mutations, which have causative roles in malignancy pathogenesis, from ‘passenger’ mutations, which are dispensable for cancer initiation and maintenance. Translational studies of clinically active targeted therapeutics can definitively discriminate driver from passenger lesions and provide valuable insights into human cancer biology. Activating internal tandem duplication (ITD) mutations in FLT3 (FLT3-ITD) are detected in approximately 20% of acute myeloid leukaemia (AML) patients and are associated with a poor prognosis. Abundant scientific and clinical evidence, including the lack of convincing clinical activity of early FLT3 inhibitors, suggests that FLT3-ITD probably represents a passenger lesion. Here we report point mutations at three residues within the kinase domain of FLT3-ITD that confer substantial in vitro resistance to AC220 (quizartinib), an active investigational inhibitor of FLT3, KIT, PDGFRA, PDGFRB and RET; evolution of AC220-resistant substitutions at two of these amino acid positions was observed in eight of eight FLT3-ITD-positive AML patients with acquired resistance to AC220. Our findings demonstrate that FLT3-ITD can represent a driver lesion and valid therapeutic target in human AML. AC220-resistant FLT3 kinase domain mutants represent high-value targets for future FLT3 inhibitor development efforts.


Nature Biotechnology | 2012

Assuring the quality of next-generation sequencing in clinical laboratory practice

Amy S. Gargis; Lisa Kalman; Meredith W Berry; David P. Bick; David Dimmock; Tina Hambuch; Fei Lu; Elaine Lyon; Karl V. Voelkerding; Barbara A. Zehnbauer; Richa Agarwala; Sarah F. Bennett; Bin Chen; Ephrem L.H. Chin; John Compton; Soma Das; Daniel H. Farkas; Matthew J. Ferber; Birgit Funke; Manohar R. Furtado; Lilia Ganova-Raeva; Ute Geigenmüller; Sandra J Gunselman; Madhuri Hegde; Philip L. F. Johnson; Andrew Kasarskis; Shashikant Kulkarni; Thomas Lenk; Cs Jonathan Liu; Megan Manion

Amy S Gargis, Centers for Disease Control and Prevention Lisa Kalman, Centers for Disease Control and Prevention Meredith W Berry, SeqWright Inc David P Bick, Medical College of Wisconsin David P Dimmock, Medical College of Wisconsin Tina Hambuch, Illumina Clinical Services Fei Lu, SeqWright Inc Elaine Lyon, University of Utah Karl V Voelkerding, University of Utah Barbara Zehnbauer, Emory University


Genome Research | 2010

Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver

Xia Yang; Bin Zhang; Cliona Molony; Eugene Chudin; Ke Hao; Jun Zhu; Andrea Gaedigk; Christine Suver; Hua Zhong; J. Steven Leeder; F. Peter Guengerich; Stephen C. Strom; Erin G. Schuetz; Thomas H. Rushmore; Roger G. Ulrich; J. Greg Slatter; Eric E. Schadt; Andrew Kasarskis; Pek Yee Lum

Liver cytochrome P450s (P450s) play critical roles in drug metabolism, toxicology, and metabolic processes. Despite rapid progress in the understanding of these enzymes, a systematic investigation of the full spectrum of functionality of individual P450s, the interrelationship or networks connecting them, and the genetic control of each gene/enzyme is lacking. To this end, we genotyped, expression-profiled, and measured P450 activities of 466 human liver samples and applied a systems biology approach via the integration of genetics, gene expression, and enzyme activity measurements. We found that most P450s were positively correlated among themselves and were highly correlated with known regulators as well as thousands of other genes enriched for pathways relevant to the metabolism of drugs, fatty acids, amino acids, and steroids. Genome-wide association analyses between genetic polymorphisms and P450 expression or enzyme activities revealed sets of SNPs associated with P450 traits, and suggested the existence of both cis-regulation of P450 expression (especially for CYP2D6) and more complex trans-regulation of P450 activity. Several novel SNPs associated with CYP2D6 expression and enzyme activity were validated in an independent human cohort. By constructing a weighted coexpression network and a Bayesian regulatory network, we defined the human liver transcriptional network structure, uncovered subnetworks representative of the P450 regulatory system, and identified novel candidate regulatory genes, namely, EHHADH, SLC10A1, and AKR1D1. The P450 subnetworks were then validated using gene signatures responsive to ligands of known P450 regulators in mouse and rat. This systematic survey provides a comprehensive view of the functionality, genetic control, and interactions of P450s.


Nature Biotechnology | 2012

A hybrid approach for the automated finishing of bacterial genomes

Ali Bashir; Aaron Klammer; William P. Robins; Chen Shan Chin; Dale Webster; Ellen E. Paxinos; David Hsu; Meredith Ashby; Susana Wang; Paul Peluso; Robert Sebra; Jon Sorenson; James Bullard; Jackie Yen; Marie Valdovino; Emilia Mollova; Khai Luong; Steven Lin; Brianna Lamay; Amruta Joshi; Lori A. Rowe; Michael Frace; Cheryl L. Tarr; Maryann Turnsek; Brigid M. Davis; Andrew Kasarskis; John J. Mekalanos; Matthew K. Waldor; Eric E. Schadt

Advances in DNA sequencing technology have improved our ability to characterize most genomic diversity. However, accurate resolution of large structural events is challenging because of the short read lengths of second-generation technologies. Third-generation sequencing technologies, which can yield longer multikilobase reads, have the potential to address limitations associated with genome assembly. Here we combine sequencing data from second- and third-generation DNA sequencing technologies to assemble the two-chromosome genome of a recent Haitian cholera outbreak strain into two nearly finished contigs at >99.9% accuracy. Complex regions with clinically relevant structure were completely resolved. In separate control assemblies on experimental and simulated data for the canonical N16961 cholera reference strain, we obtained 14 scaffolds of greater than 1 kb for the experimental data and 8 scaffolds of greater than 1 kb for the simulated data, which allowed us to correct several errors in contigs assembled from the short-read data alone. This work provides a blueprint for the next generation of rapid microbial identification and full-genome assembly.

Collaboration


Dive into the Andrew Kasarskis's collaboration.

Top Co-Authors

Avatar

Eric E. Schadt

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Robert Sebra

University of Colorado Boulder

View shared research outputs
Top Co-Authors

Avatar

Ali Bashir

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Theodore Pak

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Joel T. Dudley

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Harm van Bakel

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Deena R. Altman

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge